Table 1 Patient demographics and clinical characteristics
EM, Study NCT03303092 | CM, Study NCT03303079 | ||||
|---|---|---|---|---|---|
Placebo | Fremanezumab | Placebo | Fremanezumab | ||
(n = 117) | Monthly (n = 121) | Quarterly (n = 119) | (n = 191) | Total (n = 380) | |
Age, years, mean (SD) | 44.2 (10.7) | 44.4 (9.5) | 41.9 (10.1) | 42.1 (10.2) | 43.1 (10.2) |
Body mass index, mean (SD) | 22.8 (3.5) | 23.0 (4.0) | 22.5 (3.4) | 22.8 (3.4) | 22.9 (3.8) |
Female sex, n (%) | 100 (85.5) | 101 (83.5) | 101 (84.9) | 163 (85.3) | 328 (86.3) |
Disease history | |||||
Time since onset of migraine, years, mean (SD) | 19.4 (13.3) | 22.0 (12.9) | 18.3 (11.4) | 19.0 (11.2) | 18.5 (12.3) |
Use of preventive migraine medication at baseline, yes, n (%) | 22 (18.8) | 24 (19.8) | 23 (19.3) | 41 (21.5) | 79 (20.8) |
n = 117 | n = 121 | n = 118 | n = 191 | n = 378 | |
Disease characteristics during 28-day pretreatment period | |||||
Number of days with headache of any severity and duration, mean (SD) | 11.1 (2.5) | 11.0 (2.1) | 11.0 (2.5) | 21.2 (4.3) | 21.4 (4.0) |
Number of headache days of at least moderate severity, mean (SD) | 8.0 (2.8) | 7.6 (2.5) | 7.5 (2.8) | 13.5 (5.0) | 13.3 (5.4) |
Number of migraine days, mean (SD) | 9.0 (2.8) | 8.6 (2.5) | 8.7 (2.5) | 15.4 (5.0) | 15.8 (5.2) |
Use of any acute headache medications, yes, n (%) | 117 (100.0) | 120 (99.2) | 117 (98.3) | 191 (100.0) | 375 (98.7) |
Use of migraine-specific acute headache medications, yes, n (%) | 114 (97.4) | 115 (95.0) | 110 (92.4) | 177 (92.7) | 352 (92.6) |